Los Angeles, CA, June 19, 2002 --- Immunomedics, Inc. (Nasdaq:IMMU) today announced that a presentation at the 49th Annual Meeting of the Society of Nuclear Medicine reported on the progress of a new antibody-based therapeutic in animals with transplanted human breast cancer.

This preclinical study evaluated an antibody known as humanized RS7 (hRS7) that targets breast, lung, prostate and ovarian cancers, identifying a tumor-associated molecule named “epithelial glycoprotein-1.” In this study, the hRS7 antibody was labeled with iodine-131 (I-131) using the Company’s recently patented method that improves the length of time the I-131 stays attached to the antibody. This new labeling method resulted in 4-times the dose of I-131 delivered to the tumor, as compared to the same antibody labeled with I-131 using conventional methods. Increased exposure of the tumor to the I-131 resulted in 75% of the animals being cured.

“We believe this is a demonstrated improvement over current methods of attaching this isotope to antibodies, since conventional methods usually show rapid detachment of I-131, thus requiring an individualized dosing for each patient,” commented the Company’s President and Chief Executive Officer, Cynthia L. Sullivan. “With this new method of labeling I-131, which is an inexpensive isotope used worldwide for thyroid cancer therapy, we may be able to reintroduce it for the therapy of several different cancers to which we have developed humanized antibodies. This will allow both yttrium-90 and iodine-131 to be product choices, depending on the clinical setting and need,” Ms. Sullivan explained. “In patients with minimal disease, I-131 may be the choice therapeutic isotope, whereas Y-90 penetrates deeper into tissue, and may therefore be better for larger, bulkier tumors,” she added.

Immunomedics is a biopharmaceutical company focused on the development, manufacture and commercialization of diagnostic imaging and therapeutic products for the detection and treatment of cancer and infectious diseases. Integral to these products are highly specific monoclonal antibodies and antibody fragments designed to deliver radioisotopes and chemotherapeutic agents to tumors and sites of infection. Immunomedics has five therapeutic products in clinical trials and has two marketed diagnostic imaging products. The most advanced therapeutic product candidates are LymphoCide™ (epratuzumab), which is in Phase II and Phase III clinical trials for the treatment of non-Hodgkin’s lymphoma, and CEA-Cide™ (labetuzumab), which is in Phase I/II clinical trials for the treatment of certain solid tumors.
This release, in addition to historical information, contains forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements, including statements regarding clinical trials, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Factors that could cause such differences include, but are not limited to, risks associated with new product development (including clinical trials outcome and regulatory requirements/actions), competitive risks to marketed products and availability of financing and other sources of capital, as well as the risks discussed in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2002.

Company Contact: Rebecca Kinner, Investor Relations, (973) 605-8200, extension 263. Visit the company’s web site at http://www.Immunomedics.com

Note: Data in this release refer to SNM Abstract Number 556.